==== Front Sci Rep Sci Rep Scientific Reports 2045-2322 Nature Publishing Group UK London 78549 10.1038/s41598-020-78549-y Article Implementation of the asparaginase activity assessment technique for clinical use: experience of a Brazilian Center Cecconello Daiane Keller daia_cecconello@hotmail.com 123 Rechenmacher Ciliana 123 Werlang Isabel 23 Zenatti Priscila Pini 4 Yunes Jose Andres 4 Alegretti Ana Paula 3 Lanvers-Kaminsky Claudia 5 Daudt Liane Esteves 123 Michalowski Mariana Bohns 123 1 grid.8532.c0000 0001 2200 7498Graduate Program in Child and Adolescent Health, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS Brazil 2 grid.414449.80000 0001 0125 3761Translational Pediatrics Laboratory, Experimental Research Center, Hospital de Clínicas de Porto Alegre, Porto Alegre, RS Brazil 3 grid.414449.80000 0001 0125 3761Hospital de Clínicas de Porto Alegre, Porto Alegre, RS Brazil 4 grid.456556.1Centro Infantil Boldrini, Campinas, SP Brazil 5 grid.16149.3b0000 0004 0551 4246University Children’s Hospital of Münster, Münster, Germany 8 12 2020 8 12 2020 2020 10 2148110 7 2020 23 11 2020 © The Author(s) 2020Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.Acute lymphoid leukemia is a childhood cancer that in high-income countries has event-free survival rates of 80% and global survival rates of 90%. In Brazil these rates are under 70%. This difference may be due to the implementation of supportive care, including the assessment of asparaginase (ASNase) activity. ASNase may cause hypersensitivity reactions and silent drug inactivation. For this reason, ASNase activity monitoring is an essential tool to ensure an effective treatment. Our aim was to implement an ASNase activity measurement technique at a hospital setting. samples from children who were given Escherichia coli-derived ASNase were collected. The results of the analyses conducted in our laboratory Hospital de Clínicas de Porto Alegre were compared to those of two institutions: Centro Infantil Boldrini and University of Munster. 262 samples were assessed. The results of the first analyses were compared with those obtained at Centro Infantil Boldrini and showed an ICC of 0.954. Thirty samples were sent to the University of Munster and presented an ICC was 0.960. Our results, when compared to those of national and international centers, showed an excellent agreement. The study was able to implement an ASNase activity test to monitor the treatment. Subject terms CancerHealth careOncologyDrug discoveryissue-copyright-statement© The Author(s) 2020 ==== Body Introduction Acute lymphoid leukemia (ALL) is the most common neoplasm in children. Over the years, improvements in treatment have been observed with the use of multicenter protocols. Whereas high-income countries have event-free survival rates of 80% and global survival rates of 90%, in Brazil these rates are under 70%1. This difference is due to several factors, including supportive care with adequate monitoring of the drugs used in the protocols. Asparaginase (ASNase) activity is one of the aspects lacking assessment within our reality in Brazil. Within recent years monitoring increasingly recognized as important to manage ASNase therapy, as it provides a means of identifying patients with sub-ideal activity and provides the information necessary to make adjustments in treatment2,3. ASNase is an enzyme derived from bacteria that has an anti-leukemic function by catalyzing the hydrolysis of the amino acid l-asparagine in l-aspartic acid and ammonia, and is considered a crucial/essential component of therapies for leukemias4,5. Three different forms have been developed: one is derived from Escherichia coli, another is derived from Erwinia chrysantemi, and a third formulation, pegylated asparaginase (PEG ASNase), which is a conjugation of E. coli with polyethylene glycol and was created to reduce the immunogenic potential4,6,7. Among the adverse effects of ASNase, clinical hypersensitivity reactions were found to occur as a result of the production of anti-ASNase antibodies. These antibodies may also cause rapid enzyme inactivation without clinical signs, referred to as silent inactivation. This phenomenon may generate sub-therapeutic ASNase concentrations leading to a greater chance of relapsed disease8,9. Because of these facts, ASNase monitoring is important to predict future allergic reactions or to alert to silent inactivation1,5,10,11. The most sensitive and reproducible method with established clinical use is the assessment of ASNase activity. In addition to being related to the level of asparagine depletion, it has the best correlation with clinical efficacy. For these reasons, it is the method currently indicated for regular use in patient care. Today, regimens that achieve ASNase activity ≥ 0.1 IU/mL are considered to be effective and indicative of a better prognosis11–14. Understanding the reasons for differences in cure rates in ALL patients between Brazil and high-income countries is essential. Several studies postulate that obtaining an effective treatment requires monitoring the activity of medications6,10,15. In this study, our aim was to implement an ASNase activity technique with safety, quality, and reproducibility at a hospital setting in Brazil, in order to improve the quality of care for our patients. Methods Patients and methods In total, 262 samples were collected from 19 children who were given E. coli-derived ASNase according to the Berlin-Frankfurt-Münster BFM 2009 ALL protocol at Hospital de Clínicas de Porto Alegre (HCPA), a university hospital in Porto Alegre, southern Brazil, between April 2017 and December 2017. A minimum 2 mL of blood sample in ethylenediaminetetraacetic acid (EDTA) were collected 24 h and 48 h after each ASNase infusion. Samples were centrifuged at 3670 rpm for 10 min and stored a maximum of 2 h after collection. All procedures and protocols were approved by the Research Ethics Committee of the Hospital de Clinicas de Porto Alegre (CEP/HCPA) under the number CAAE 69093817.4.0000.5327. Furthermore, all experiments were carried out respecting the appropriate guidelines and all individuals who participated in the study confirmed informed consent, including those who were under 18, who had the informed consent of legal guardians. Comparative analysis of results To confirm the successful set up/establishment of the AHA method at our hospital Seventeen analyses were performed at Hospital Boldrini (HB, Campinas, Brazil), which performed the tests only on animals, to practice the technique and establish the critical points of the protocol. Subsequently, 30 samples were sent to the University of Munster (UM, Munster, Germany), a European center of excellence in the analysis of ASNase activity. The activity of 262 samples was evaluated in our center, based on the reactions of the below-described method, which were classified according to the activity level as above or below 0.1 IU/mL16. The method of analysis used by all centers to determine enzyme activity was based on a technique described by Lanvers et al.10 which uses aspartic acid B-hydroxamate (AHA) as a substrate for the quantification of ASNase derived from E. coli, Erwinia chrysanthemi, and PEG ASNase in human plasma. For determination of ASNase activity, we used E.coli ASNase concentrations between 0.0025 IU/mL and 0.1 IU/mL for the standard curve. Samples with activity > 0.1 IU/mL were repeated on a standard curve with concentrations between 0.1 and 1 IU/mL of.E.coli ASNase. Twenty µl of plasma were diluted with 180 µL of a 2 mM AHA solution dissolved in Tris buffer, pH 7.3 (0.015 M), supplemented with 0.015% (w/v) bovine serum albumin (BSA), and incubated for 30 min at 37 °C. Then, 50 µL of the resulting supernatant were added to a new plate to react with 200 µL of oxin reagent, which consisted of one part of 2% 8-hydroxyquinoline dissolved in absolute ethanol (w/v) and three parts of 1 M sodium carbonate solution. After heating the plate at 95 °C for 1 min and cooling it down for exactly 10 min, absorbance was measured at 690 nm in a SpectraMax M3 equipment (Fig. 1). The standards and samples were analyzed in duplicate, and the control was read in triplicate.Figure 1 Mechanism of action of asparaginase and reaction of the indooxin method, based on the hydrolysis of l-aspartic b-hydroxamate (AHA), to determine enzyme activity. Figure adapted from Lanvers et al.10. Precision was determined by analyzing plasma samples from the standard curve in concentrations (1; 0.5 and 0.15 IU/mL) with five repetitions (intraday precision = analyzes performed on the same day; inter-day precision = analyzes performed on different days with up to 5 days apart). The acceptance criterion used is the coefficient of variation (CV) < 20% for precision10. Results Table 1 shows the results of the 262 samples taken 24 and 48 after the infusion and expresses the results in median and interquartile range. The results of the first 17 analyses were compared to those obtained at HB. The results are shown in Table 2 and had an intraclass correlation coefficient (ICC) of 0.954.Table 1 Medians of enzyme activity evaluated at 24 h and 48 h after infusion. Time post-infusion (h) n Median (IU/mL) [Q1;Q3] (IU/mL) 24 131 0.066 [0.049; 0.260] 48 131 0.020 [0.011; 0.084] Data are presented as medians and interquartile ranges. Table 2 Comparative results of Escherichia coli-derived ASNase activity (IU/mL) between Centro Infantil Boldrini (CIB, Campinas, Brazil) and Hospital de Clínicas de Porto Alegre (HCPA, Porto Alegre, Brazil). Sample CIB IU/mL HCPA IU/mL 8 A1 − 0.004 − 0.002 17 A1 − 0.004 − 0.002 17 C1 0.025 0.030 17 C2 0.017 0.018 17 C3 0.018 0.022 17 C4 0.016 0.017 17 C5 0.005 0.007 17 C6 − 0.004 − 0.001 17 C7 − 0.004 − 0.002 19 A1 − 0.004 − 0.003 19 C1 0.004 0.006 19 C2 0.011 0.014 19 C3 0.014 0.014 19 C5 0.011 0.011 19 C6 0.012 0.013 19 C7 0.008 0.008 19 C8 − 0.003 − 0.001 CIB Centro Infantil Boldrini (Brazil), IU International units; Intraclass correlation coefficient = 0.954. Thirty samples from patients who were given ASNase were then sent to the UM in Germany. The results obtained there are shown in Table 3 and compared to the results obtained at our institution. ICC was 0.960, showing agreement. The precision varied between 5.39 and 5.70% for samples analyzed on the same day (intra-day) and between 5.43 and 6.01% for samples analyzed on different days (inter-days), as shown in Table 4.Table 3 Comparative results of Escherichia coli-derived ASNase activity (IU/mL) between the University of Munster (UM, Munster, Germany) and Hospital de Clínicas de Porto Alegre (HCPA, Porto Alegre, Brazil). Sample UM IU/mL HCPA IU/mL 6B5 0.600 0.770 6C5 0.221 0.290 6B6 0.281 0.360 7B1 0.610 0.582 7C1 0.283 0.221 7C2 0.310 0.253 7B3 0.101 0.140 7C5 0.021 0.022 7B7 0.091 0.101 8B2 0.642 0.661 8C2 0.262 0.264 8C3 0.024 0.032 9C8 0.011 0.021 9B9 0.743 0.922 10B2 0.070 0.082 10B8 0.090 0.084 12A1 0.000 0.001 12B2 0.090 0.083 12C5 0.021 0.020 14C3 0.020 0.022 14C5 0.032 0.030 14B9 0.113 0.172 15B1 0.074 0.080 16C1 0.050 0.051 16B3 0.123 0.161 17C2 0.022 0.012 17B5 0.071 0.024 18B2 0.141 0.221 20B1 0.240 0.392 UM University of Munster (Germany), HCPA Hospital de Clínicas de Porto Alegre (Brazil), IU International units; Intraclass correlation coefficient = 0.960. Table 4 Intra-day and inter-day precision for the analytical method. Range (IU/mL) Intraday CV (%) Interday CV (%) 1 5.39 5.43 0.5 5.54 5.56 0.15 5.70 6.01 CV coefficient of variation. Discussion ASNase is an important component of the treatment of children with ALL. However, it may cause complications because of some side effects of the enzyme; also, it may be inactivated by the production of antibodies, leading to decreased treatment effectiveness17. Adequate levels of ASNase activity are known to result in depletion of asparagine and are of critical importance for patients undergoing treatment for ALL17,18. Accurate measurement of serum asparagine in patients may be hindered by continuous enzymatic hydrolysis, since ex vivo metabolism may continue to occur after blood collection, providing an erroneous reading19,20. For this reason, Albersten et al.21 recommended monitoring the activity levels of the enzyme ASNase and measuring the levels of antibodies. However, measurement of antibodies is not correlated with clinical repercussion for the treatment of each patient, as there is no clear association between antibody titer and level of enzyme activity22. Thus, measurement of ASNase activity levels, as reported in several studies, can be used as a substitute for standardizing asparagine depletion during therapy12,23. To measure the level of substrate conversion, several quantification methods were developed based on the determination of aspartate or ammonia (NH3) that was produced. The released NH3 can be measured by methods involving reactions with colorimetric reagents, such as Nessler or indophenol, followed by spectrophotometric determination24. These methods detect amounts of ASNase in human plasma as low as 0.02 IU/mL10,25. The Nessler method exhibits good reproducibility and high level of detection but requires caution because it involves the use of highly toxic reagents. Besides, reaction temperature and color equilibration time affect the color development of the solution, which contributes to variation in the results for this method24. As asparagine depletion is still observed at ASNase concentrations of 0.02 IU/mL, more sensitive methods are needed to determine ASNase activity in human plasma and detect silent inactivation10. Methods for determining aspartate include high-performance liquid chromatography (HPLC), electrophoresis assays, and colorimetric assay with hydroxylamine. Lanvers et al.10 have described the development of an indooxin method for quantification of three different preparations of ASNase in human plasma, a technique that we used in this study. The technique is based on the hydrolysis of AHA, which releases hydroxylamine, which in turn reacts with 8-hydroxyquinoline at alkaline pH. This method produces an intensely green pigment, easily detectable at a range between 690 and 710 nm. This method has a limit of detection as low as 1 × 10–5 IU/mL in human plasma but also has a limited working pH range due to hydroxylamine instability above neutrality10,24. HPLC-based methods overcome the disadvantages of colorimetric methods, showing excellent reproducibility, precision, and linearity when compared, but they have the disadvantage of resulting in higher costs, making them almost unfeasible for analysis of a large number of samples24,26. Therefore, the method described in this study is the most suitable for routine analysis. The standardization of ASNase quantification by a simple, reliable, fast, and robust method is very useful to overcome the disadvantages of the great disparity between existing methods for determining enzyme activity. With a lack of standardized protocols and pharmaceutical quality control guidelines, standard protocols for measuring the activity of ASNase preparations are rarely reported23,24. ICC is a measure of agreement with ability to identify identical results, being one of the most widely used statistical tools to determine the reliability of measurements. An ICC ≥ 0.75 is considered excellent for data reproducibility27. In this study, ICCs of 0.954 and 0.960 ensured agreement between the results of our center and those of HB and UM, respectively. The technique showed reproducibility and precision. The present study was able to implement an ASNase activity test for monitoring the treatment of patients with ALL, allowing for possible adjustments. Our results, when compared to those of other centers, showed excellent agreement. Importantly, to our knowledge, no laboratory in Brazil had yet routinely monitored the biological activity of this enzyme in patients, although there is already a consensus with expert recommendations for its use. As far as we know, this study was a pioneer in our country in the assessment of ASNase activity in humans. As previously mentioned, the data were obtained at two different and independent oncology centers in Brazil and at an international center using a well-established protocol. Several reports from European groups have indicated the importance of monitoring ASNase activity to prescribe appropriate treatment, as different methods of administration, formulations, doses, and immune responses may generate substantial variation in ASNase activity levels, as well as the interpersonal response10,18. Our study highlights the importance of following the recommendations of international experts for careful handling. The establishment of an appropriate technique allows expanding the availability of this type of assessment to children from other centers. Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Acknowledgements This study was funded by Coordenacão de Aperfeiçoamento de Pessoal de Nível Superior (CAPES), Fundação de Amparo à Pesquisa do Estado do Rio Grande do Sul (FAPERGS), Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), and Fundo de Incentivo à Pesquisa e Eventos do Hospital de Clínicas de Porto Alegre (FIPE/HCPA). Author contributions M.B.M. initiated the design of this study. D.K.C., C.R. and I.W. performed laboratory tests. D.K.C. and M.B.M. wrote the manuscript. L.E.D., C.L.K., J.A.Y., P.P.Z. and A.P.A. provided important clinical insights and helped with the interpretation of variants. All authors have seen and approved the manuscript. Competing interests The authors declare no competing interests. ==== Refs References 1. Pieters R l -Asparaginase treatment in acute lymphoblastic leukemia: A focus on Erwinia asparaginase Cancer 2012 102 238 249 2. Asselin B Asparaginase pharmacokinetics and implications of therapeutic drug monitoring Leukemia Lymphoma 2015 56 2273 2280 10.3109/10428194.2014.1003056 25586605 3. Avramis VI Tiwari PN Asparaginase (native ASNase or pegylated ASNase) in the treatment of acute lymphoblastic leukemia Int. J. Nanomed. 2006 1 241 254 4. Schrey D Therapeutic drug monitoring of asparaginase in the ALL-BFM 2000 protocol between 2000 and 2007 Pediatr. Blood Cancer. 2010 54 952 958 10.1002/pbc.22417 20108339 5. Rizzari C Optimizing asparaginase therapy for acute lymphoblastic leukemia Curr. Opin. Oncol. 2013 25 S1 S9 10.1097/CCO.0b013e32835d7d85 6. Fernandez CA Successful challenges using native E. coli asparaginase after hypersensitivity reactions to PEGylated E. coli asparaginase Cancer Chemother. Pharmac. 2014 73 1307 1313 10.1007/s00280-014-2464-2 7. Petersen WC Comparison of allergic reactions to intravenous and intramuscular pegaspargase in children with acute lymphoblastic leukemia J. Pediatr. Hematol. Oncol. 2014 31 311 317 10.3109/08880018.2013.876134 8. Gupta S Impact of asparaginase discontinuation on outcome in childhood acute lymphoblastic leukemia: A report from the Children's Oncology Group J. Clin. Oncol. 2020 38 1897 1905 10.1200/JCO.19.03024 32275469 9. Vrooman LM Post induction dexamethasone and individualized dosing of Escherichia coli l- asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: Results from a randomized study—Dana-Farber Cancer Institute ALL Consortium Protocol 00–01 J. Clin. Oncol. 2013 31 1202 1210 10.1200/JCO.2012.43.2070 23358966 10. Lanvers C Analytical validation of a microplate reader-based method for the therapeutic drug monitoring of l- asparaginase in human serum Anal. Bioanal. Chem. 2002 309 117 126 11. Van Der Sluis IM Consensus expert recommendations for identification and management of asparaginase hypersensitivity and silent inactivation Haematologica 2016 101 279 285 10.3324/haematol.2015.137380 26928249 12. Panosyan EH Asparaginase antibody and asparaginase activity in children with higher-risk acute lymphoblastic leukemia: Children’s Cancer Group Study CCG-1961 J. Pediatr. Hematol. Oncol. 2004 26 217 226 10.1097/00043426-200404000-00002 15087948 13. Barba P Asparaginase use for the treatment of acute lymphoblastic leukemia Med. Clin. 2017 148 225 231 10.1016/j.medcli.2016.12.006 14. Salzer W Asparaginase activity levels and monitoring in patients with acute lymphoblastic leukemia Leuk. Lymphoma 2018 59 1797 1806 10.1080/10428194.2017.1386305 29045165 15. Cecconello DK Asparaginase: An old drug with new questions Hematol. Transf. Cell Therap. 2019 1379 30142 30147 16. Cecconello DK Monitoring asparaginase activity in middle-income countries Lancet Oncol. 2018 2045 30584 30589 17. Shrivastavaa A Recent developments in l- asparaginase discovery and its potential as anticancer agent Conflict of interest: Authors declare no conflict of interest Crit. Rev. Oncol. Hematol. 2016 100 1 1 10.1016/j.critrevonc.2015.01.002 25630663 18. Asselin B Measurement of serum l- asparagine in the presence of Lasparaginase requires the presence of an l- asparaginase inhibitor Cancer Res. 1991 51 6568 6573 1742729 19. Gentili D Determination of l- asparagine in biological samples in the presence of l- asparaginase J. Chromatogr. B Biomed. Appl. 1994 657 47 52 10.1016/0378-4347(94)80068-5 7952083 20. Lanvers-Kaminsky C Immediate cooling does not prevent the ex vivo hydrolysis of l- asparagine by asparaginase Ther. Drug Monit. 2014 36 549 552 10.1097/FTD.0000000000000030 24342897 21. Albersten BK Asparaginase treatment in infants with acute lymphoblastic leukemia; pharmacokinetics and asparaginase hypersensitivity in Interfant-06 Leuk. Lymphoma 2019 60 1 7 10.1080/10428194.2018.1482547 29979098 22. Kloos RQ Allergic-like reactions to asparaginase: Atypical allergies without asparaginase inactivation Pediatr. Blood Cancer. 2016 63 1928 1934 10.1002/pbc.26123 27376478 23. Grigoryan RS Changes of amino acid serum levels in pediatric patients with higher-risk acute lymphoblastic leukemia (CCG-1961) In Vivo 2004 18 107 112 15113036 24. Magri A A critical analysis of l- asparaginase activity quantification methods—colorimetric methods versus high-performance liquid chromatography Anal. Bioanal. Chem. 2018 410 6985 6990 10.1007/s00216-018-1326-x 30155702 25. Boos J Monitoring of asparaginase activity and asparagine levels in children on different asparaginase preparations Eur. J. Cancer. 1996 32 1544 1550 10.1016/0959-8049(96)00131-1 26. Nath CE An isocratic fluorescence HPLC assay for the monitoring of l- asparaginase activity and l- asparagine depletion in children receiving E. colil -asparaginase for the treatment of acute lymphoblastic leukaemia Biomed. Chromatogr. 2009 23 152 159 10.1002/bmc.1096 18823071 27. Prieto L The evaluation of agreement on continuous variables by the intraclass correlation coefficient J. Epidemiol. Community Health 1997 51 579 581 10.1136/jech.51.5.579-a